ROQ.L
Roquefort Therapeutics plc [ROQ.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ROQ.L Stock Summary
Top 10 Correlated Stocks
ROQ.L
In the News
ROQ.L Financial details
Company Rating
-
Market Cap
5.94M
Income
-2.45M
Revenue
300K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
03 Jun 2024
P/E
-4.64
Forward P/E
-
PEG
0.94
P/S
-
P/B
1.04
P/C
-
P/FCF
-5.94
Quick Ratio
8.31
Current Ratio
8.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-57.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
100%
EPS Q/Q
100%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-21%
ROE
-29%
ROC
-0.22%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.85-9.5
52W High
-81.67%
52W Low
-45%
RSI
41
Rel Volume
5.92
Avg Volume
344.39K
Volume
2.04M
Perf Week
-10.81%
Perf Month
-25%
Perf Quarter
-70.54%
Perf Half Y
-62.92%
-
-
-
-
Beta
-0.088
-
-
Volatility
0.07%, 0.17%
Prev Close
-10.81%
Price
1.65
Change
-8.84%
Company Profile
- Volume Average 344.39K
- Market Capitalization 5.94M
- Employee 9
- CEO Mr. Trevor Ajanthan Reginald
- Headquarters London,GB
- IPO Date 2021-03-22
-
Website
https://www.roquefortinvest.com 
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
